---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-043229"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T22:40:56.598459+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma licenses BLEX 404 for TNBC to OncoX in deal worth up to $13.75M plus royalties

## Summary
- Definitive license agreement with OncoX BioPharma for exclusive rights to develop and commercialize BLEX 404 for TNBC in 50% of worldwide markets for 20 years.
- Total license fee of $6.25M (or 1.25M OncoX shares at $5/share) due 30 days after signing; additional milestone of $625k cash after OncoX's next fundraising (no guarantee).
- ABVC and its subsidiary BioLite each signed identical agreements; aggregate potential payments including royalties up to $13.75M (press release states $12.5M license fee and $1.25M milestone).
- Royalties of 5% of net sales on licensed product, up to $12.5M, starting from first commercial sale (uncertain).
- US FDA has approved four INDs for ABVC's BLEX 404 combination therapy, including for TNBC (IND 129575).

## SEC filing metadata
- accession: 0001213900-24-043229
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390024043229/0001213900-24-043229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390024043229/ea0206070-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-043229
- JSON: https://secwatch.observer/filing/0001213900-24-043229.json
- Plain text: https://secwatch.observer/filing/0001213900-24-043229.txt

## Key facts
- Material Agreements
  ABVC BIOPHARMA, INC. entered into Oncox Agreement with OncoX BioPharma, Inc. valued at Total of $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share) and an additional milestone p (effective 2024-05-14).
  - Action: entry
  - Agreement: license
  - Counterparty: OncoX BioPharma, Inc.
  - Value: Total of $6,250,000 (or 1,250,000 Oncox shares valued at $5 per share) and an additional milestone p
  - Effective: 2024-05-14
  source text: On May 14, 2024, the Company entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands (“ Oncox ”), pursuant to which the Company will grant Oncox an exclusive right to develop and commercialize ABVC’s BLEX 404 single-herb botanical drug extract from the dry fruit body of Maitake Mushroom (Grifola Frondosa) for treatment of Tripple Negative Breast Cancer (the “ Licensed Products ”), within a certain territory, specified as 50% of the Worldwide Markets for 20 years (the “ Oncox Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390024043229/0001213900-24-043229-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.